Methylene Blue Intravenously and Chronic Neuropathic Pain
CompletedNot applicableNCT02303886
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Aim of Investigation Methylene blue (MB) is a diaminophenothiazine with antioxidant, anti-inflammatory properties and with inhibitory effects on nitric oxide. The aim of this study was to determine the clinical effectiveness of MB in the treatment of neuropathic pain. Methods Ten patients with neuropathic pain were randomized to receive one of the two treatments: methylene blue (MB1) 2 mg/kg (10 mg/mL Methyltioninklorid, Apoteket, Umeå, Sweden) or methylene blue (MB2) 0.02 mg/kg. Both MB solutions were infused intravenously over 60 minutes. The sensory function and the pain were evaluated at baseline and at 60 min after the start of infusions. A pain journal was kept by the patients in the following 5 days. Plasma and urinary concentrations of 8-isoprostane-prostaglandin F2α (8-iso-PGF2α) an indicator of oxidative injury, were measured with radioimmunoassay (RIA). A panel of 92 proteins biomarkers were determined with Proximity Extension Assay (PEA) prior and after infusions. comparison with the control group. MB infusion produced an enhancement of prolactin.
Study details
- Official title
- Evaluation of the Effects of Methylene Blue on Neuropathic Pain and Protein Biomarkers
- Conditions
- Interventions
- Drug: Methylene blue
- Drug: Methylene blue
- Sponsor
- Uppsala University
- Start date
- 2009-03
- Primary completion
- 2012-06
- Sex
- All
- Age range
- from 18 Years to 75 Years
- Results posted
- No results posted in this snapshot
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Female or male subjects \> 18 years of age * Be able to understand and comply with the requirements of the study * Patients with a history of persistent peripheral and central neuropathic pain interfering with daily activities of at least 3 months duration * Patients with previous unsuccessful treatment of neuropathic pain * Spontaneous or evoked pain upon standardized test (mechanical, movement)\> 50 on a 100 mm VAS scale * Informed written consent Exclusion Criteria: * Any condition that may confound assessment of pain (acute pain) * Any condition/disease that could interfere with the study measurements, e.g. peripheral vascular disease, diabetes mellitus, alcohol/opioids addiction * Noncooperation, insufficient Swedish language * Treatment with antidepressants, antiepileptics, opioids, lidocaine patches was not accepted the day before and the day of the visit * Pregnancy * Treatment with NO releasing drugs, anti-cytokine therapy * Diabetes mellitus type I, malignancy, increased pulmonary hypertension, cardiac ischemic disease, decreased glomerular filtration rate\<30 ml/min, decreased liver function, Glu-6-PDH deficiency
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02303886